GET DAILY SIGNALSPassage Bio (PASG) +19% Rebound: Tracking the Remix Therapeutics Merger Progress
Key Takeaways
- Passage Bio (PASG) gained roughly 19% over the last 30 days, rebounding from about $3.50 to $4.16 as merger-related milestones advanced.
- The move was concentrated in early-to-mid November, following stockholder approval of the Remix Therapeutics merger and the release of third-quarter results.
- Passage Bio is pivoting from AAV gene therapy to RNA medicines through an all-stock merger with Remix Therapeutics, expected to close in the fourth quarter of 2026.
- Over the trailing three months, the stock remains down about 9%, reflecting deal dilution and earlier strategic uncertainty.
- A concurrent private placement of roughly $100 million, led by Decheng Capital, is expected to support the combined company's cash runway into 2028.
Passage Bio (PASG) Company Background and Strategic Shift
Passage Bio, Inc. is a Philadelphia-based clinical-stage genetic medicines company incorporated in 2017. Historically, the company focused on developing one-time, adeno-associated virus (AAV)-based gene therapies for rare, monogenic central nervous system disorders. Its lead program, PBFT02, is an AAV1-delivered gene therapy designed to elevate progranulin levels for the treatment of frontotemporal dementia caused by GRN mutations (FTD-GRN). Passage Bio also previously advanced pediatric programs targeting GM1 gangliosidosis and Krabbe disease, which have since been out-licensed to GEMMA Biotherapeutics.
Investors follow the stock primarily for its strategic transformation. In 2026, Passage Bio agreed to an all-stock merger with Remix Therapeutics, a privately held company built on a platform that reprograms RNA processing. Remix's lead candidate, REM-422, is an oral mRNA degrader targeting the oncogenic transcription factor MYB, with clinical programs in adenoid cystic carcinoma and acute myeloid leukemia/high-risk myelodysplastic syndromes. Upon closing, the combined company is expected to operate as Remix Therapeutics, with existing Passage Bio stockholders holding a small minority stake of roughly 6%.
Passage Bio (PASG) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PASG climbed approximately 18.9%, rising from a closing price of $3.50 on October 16, 2026, to $4.16 on November 13, 2026. The advance was not linear: the stock touched a low near $3.33 in late October before turning higher as merger milestones came into focus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The broader quarterly picture is more mixed. From a closing level of about $4.59 in mid-August, the stock declined roughly 9% through mid-November. That period featured significant volatility, including a rally toward $5.00 in September, a sharp selloff through October, and the November rebound. The net result highlights how strategic uncertainty weighed on shares before the recent recovery.
What Drove PASG Stock Price in the Last 30 Days
The recent advance was driven primarily by progress on the Remix Therapeutics merger and by improving financial results. On November 5, 2026, Passage Bio stockholders approved the merger-related proposals, including the issuance of shares representing a change of control, a reverse stock split ranging from 1-for-2 to 1-for-10, and a charter amendment to rename the company Remix Therapeutics, Inc. That approval removed a key uncertainty surrounding deal completion.
On November 10, 2026, the company reported third-quarter results showing a narrowed net loss of $4.7 million, down from $7.7 million in the prior-year period, alongside reduced operating expenses. Management reaffirmed the expectation that the merger would close in the fourth quarter of 2026 and noted the concurrent financing of approximately $100 million in gross proceeds. These developments helped restore investor confidence and supported the stock's climb from its late-October lows.
What Drove PASG Stock Performance Over the Last Quarter
The quarterly trend reflects a fundamental strategic pivot. After winding down its gene therapy programs, Passage Bio announced the Remix Therapeutics merger in June 2026 and amended the agreement terms in September. While the deal offers a path to a well-funded RNA therapeutics platform, it also implies substantial dilution for existing holders, who are expected to own only a small percentage of the combined company. That dilution, combined with the company's reduced pipeline activity and thin cash balance of $20.2 million at September 30, 2026, pressured the stock through October. The November rebound suggests investors have begun pricing in deal completion and the combined entity's projected cash runway into 2028.
PASG Stock Forecast Drivers: What Investors Should Watch Next
The most important near-term catalyst is the completion of the Remix Therapeutics merger, expected in the fourth quarter of 2026, along with the finalization of the concurrent financing and the associated reverse stock split. Investors should also monitor clinical data readouts for REM-422 across its oncology indications, as well as the combined company's cash position and stated runway into 2028. Additional factors to watch include the outcome of any regulatory milestones, competitive developments in RNA-targeting oncology, and broader sentiment across small-cap and clinical-stage biotechnology names. These events carry meaningful execution and scientific risk, and investors should evaluate them within the context of their own objectives and risk tolerance. From what I see, this is important because timing around these catalysts can shift sentiment quickly.
Exploring Tickeron’s AI Trading Bots for Market Insights
In my research process, I often review Tickeron’s AI Trading Bots to compare automated strategies across different timeframes and risk levels. The platform surfaces top-performing bots that monitor equities and other assets, allowing users to examine metrics like holding periods and historical performance before deciding on an approach. It provides a practical way to test ideas alongside manual analysis without replacing individual judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
PASG in upward trend: price rose above 50-day moving average on November 13, 2026
PASG moved above its 50-day moving average on November 13, 2026 date and that indicates a change from a downward trend to an upward trend. In 31 of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PASG's RSI Indicator exited the oversold zone, 28 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on PASG as a result. In 87 of 103 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for PASG just turned positive on October 29, 2026. Looking at past instances where PASG's MACD turned positive, the stock continued to rise in 42 of 48 cases over the following month. The odds of a continued upward trend are 88%.
Following a +4.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where PASG advanced for three days, in 172 of 212 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PASG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
PASG broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PASG entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. PASG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.870) is normal, around the industry mean (3.498). P/E Ratio (-0.351) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PASG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a genetic medicines company, which focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options
Industry Biotechnology
Advertisement